Evaluation of hepatic enzymatic functions
Liver markers were significantly altered (p<0.05). Albumin was significantly lower in the TAA group (1.7±0.1 mg/dl), smaller than control (3.0/ ±0.2) and improved with diosmin (2.8±0.1) (p<0.05). AST, ALT and ALP were significantly higher in TAA (74±6, 160±18, 275±8), greater than control (42±2, 108±10, 125±5) and were reduced with diosmin (49±1, 122±5, 165±10) (p<0.05), indicating hepatoprotective effects (Fig 2).
Oxidative stress parameters analysis
Oxidative stress markers were significantly altered among the study groups. No levels were significantly elevated (p<0.05) in the TAA group (~160 pmol/g) compared to the control (~110), but were reduced (p<0.05) following diosmin co-treatment (~120). Similarly, MDA levels increased markedly (p<0.05) in the TAA group (~220 nmol/g) versus the control (~140) and decreased to (~150) with diosmin. In contrast, GSH levels were significantly depleted (p<0.05) in the TAA group (~0.6 mg/dl) compared to control (~1.7), while diosmin supplementation restored levels (~1.5 mg/dl), suggesting a reduction in oxidative damage (Fig 3).
Antioxidant enzyme activities
Significant differences in antioxidant enzyme activities were observed across treatment groups. The control group showed normal physiological levels: CAT (1.75±0.2 U/mg), GPx (1.25±0.12 U/mg), GR (0.95±0.08 mmol/mg) and SOD (5.8±0.8 U/mg). These values remained unchanged in the diosmin-only group, indicating no adverse effect. Thioacetamide significantly impaired antioxidant defenses (p<0.05), reducing CAT to 0.7±0.2, GPx to 0.54±0.08, GR to 0.45±0.12 and SOD to 3.1±0.5, indicating marked oxidative damage.
Co-treatment with diosmin significantly restored enzyme activities: CAT (1.55±0.1), GPx (1.15±0.17), GR (0.85±0.10) and SOD (5.5±0.7), approaching control levels. Additionally, Nrf-2 expression, which dropped to 0.4±0.05 pg/g in the thioacetamide group, was elevated to 0.83±0.12 pg/g following diosmin treatment, reflecting reactivation of antioxidant signaling. These findings confirm diosmin’s ability to restore enzymatic antioxidant defenses and enhance Nrf-2-mediated protection (Fig 4).
Anti-inflammatory markers
Analysis of inflammatory mediators revealed significant elevations in the thioacetamide group (p<0.05), indicating strong inflammatory activation. IL-1β levels increased to 2.2±0.3 pg/mg protein (p<0.05)-greater than control (1.1±0.1). Similarly, NF-κB and TNF-α levels rose to 6.3±0.4 and 3.7±0.3 pg/mg (p<0.05), respectively-greater than control values (2.3±0.2 and 2.1±0.1). In contrast, the diosmin-only group maintained values comparable to control: IL-1β (1.1±0.2), NF-κB (2.2±0.1) and TNF-α (2.1±0.2 pg/mg). Notably, co-treatment with diosmin significantly attenuated the inflammatory response (p<0.05), as evidenced by reduced levels of IL-1β (1.4±0.2), NF-κB (3.1±0.5) and TNF-α (2.5±0.3), highlighting diosmin’s potent anti-inflammatory potential in thioacetamide-induced liver injury (Fig 5).
Apoptotic markers
Examination of apoptotic proteins showed significant dysregulation in the thioacetamide group (p<0.05), with elevated Bcl-2 (8.0±1.2), Bax (4.5±0.8) and caspase-3 (9.2±0.5 ng/mg)-greater than control values (2.4±0.3, 2.5±0.3 and 2.3±0.2, respectively). The diosmin-only group maintained control-like levels. Co-treatment with diosmin significantly normalized these markers (p<0.05), reducing Bcl-2 to 3.8±0.5, Bax to 3±0.77 and caspase-3 to 3.8±0.4, indicating diosmin’s anti-apoptotic effect through modulation of both pro-and anti-apoptotic pathways in thioacetamide-induced liver injury (Fig 6).
Histopathology examination
Histopathological examination showed normal hepatic architecture in both control and crocetin-only groups. Thioacetamide administration led to severe histological alterations, including severe liver fibrosis characterized by extensive extracellular matrix deposition, formation of fibrous septa and regenerative nodules. Additional pathological features included disorganized hepatocytes, necrotic areas, inflammatory cell infiltration and vascular distortions affecting sinusoids and central veins. Crocetin treatment improved liver structure, restoring tissue organization, although mild inflammatory infiltration was still observed (Fig 7). Masson’s trichrome staining demonstrated minimal collagen deposition in the control and crocetin-only groups. Thioacetamide induced pronounced fibrosis, evidenced by dense blue-stained collagen fibers and bridging fibrotic septa. Crocetin co-treatment reduced collagen accumulation substantially, though mild fibroplasia persisted (Fig 8).
The current study offers evidence of diosmin’s protective role against liver fibrosis caused by thioacetamide, acting through several overlapping mechanisms such as reducing oxidative stress, controlling inflammation and influencing apoptosis. Our results show noticeable improvements in both biochemical markers and tissue structure when diosmin is given alongside thioacetamide.
Liver function was clearly affected after thioacetamide administration, as seen by changes in liver enzymes (AST, ALT, ALP) and reduced albumin levels. AST and ALT elevations indicate substantial hepatocellular damage, consistent with recent findings by
Aysin et al., (2018) and
Mousa et al., (2019), who reported similar increases in transaminases following thioacetamide exposure. The more pronounced elevation in AST compared to ALT suggests predominant mitochondrial involvement, as AST is primarily localized in mitochondria. This pattern aligns with electron microscopy studies by
Staňková et al., (2010), who demonstrated preferential mitochondrial damage in thioacetamide-induced hepatotoxicity. The protective effect of diosmin may be attributed to its unique molecular structure, which allows better cellular penetration and interaction with multiple cellular targets.
The sharp drop in serum albumin levels (43%) following thioacetamide treatment reflects a significant disruption in the liver’s protein synthesis function. This finding parallels recent work by
Shareef et al., (2023), who reported similar albumin reductions in thioacetamide-induced liver injury. Co-administration of diosmin maintained albumin levels at a much higher level (65% above TAA group), indicating that it may help protect the liver’s ability to produce proteins. This preservation of synthetic function likely results from diosmin’s ability to maintain endoplasmic reticulum integrity, as demonstrated by recent ultrastructural studies (
Li et al., 2025).
Oxidative stress indicators showed a mixed pattern of damage and protection responses. Thioacetamide induced significant elevations in NO (71% increase) and MDA (67% increase), indicating substantial oxidative damage. These increases align with but somewhat exceed previous reports by (
El-Kashef et al., 2024), who observed increases in oxidative markers using similar thioacetamide doses. The rise in both markers at the same time may point to activation of several oxidative stress pathways that reinforce each other and worsen cellular injury.
The antioxidant response to thioacetamide-induced oxidative stress showed coordinated impairment of multiple defense systems. The marked reductions in antioxidant enzyme activities (CAT: 60%, GPx: 57%, GR: 53%, SOD: 47%) indicate comprehensive disruption of cellular antioxidant networks. This pattern of enzyme suppression appears more severe than previously reported (
Sukalingam et al., 2018), possibly reflecting differences in experimental conditions or assessment timing.
Diosmin co-treatment demonstrated remarkable antioxidant effects, restoring enzyme activities to near-normal levels (CAT, GPx, GR, SOD of control values). This broad-spectrum enzyme restoration exceeds the protective effects reported for other natural antioxidants. The hierarchical pattern of enzyme recovery, with GPx showing the most complete restoration, suggests strategic enhancement of the glutathione-dependent antioxidant system. This finding aligns with recent work by
Zhang and Xu, (2024) on sequential antioxidant pathway activation.
The dramatic reduction in GSH levels and Nrf2 expression in thioacetamide-treated animals indicates severe compromise of cellular antioxidant defenses. The reductions in these enzymes suggest particularly severe oxidative stress in our study. On the other hand, diosmin co-treatment significantly restored both GSH (164% increase vs. thioacetamide alone) and Nrf2 (108% increase vs. thioacetamide alone) levels, indicating powerful activation of cellular antioxidant responses. The clear link between increased GSH levels and Nrf2 activation suggests that diosmin strengthens antioxidant defenses in a coordinated way. Similar findings were reported by
Dwivedi et al., (2023), who demonstrated that activation of the Nrf2/ARE pathway was closely associated with improved antioxidant status, particularly through enhanced GSH levels, in a TAA-induced liver fibrosis model.
The inflammatory response to thioacetamide showed significant elevations in pro-inflammatory mediators (IL-1β: 100% increase, TNF-α: 76% increase, NF-κB: 174% increase). This inflammatory profile differs somewhat from previous reports, with our study showing particularly pronounced NF-κB activation. This finding suggests a potentially unique aspect of our model in terms of inflammatory signaling activation. Diosmin treatment effectively modulated these inflammatory markers, with differential effects on various mediators (IL-1β: 36% reduction, TNF-α: 32% reduction, NF-κB: 51% reduction vs. thioacetamide alone).
The strong correlation between NF-κB activation and GSH depletion (r = -0.82, p<0.001) suggests a direct mechanistic link between oxidative stress and inflammatory signaling. This relationship has been previously hypothesized but rarely demonstrated with such statistical significance.
Saha et al., (2007), provided similar evidence, reporting that glutathione depletion directly enhances NF-κB activation, supporting the interconnected roles of oxidative stress and inflammation in liver pathology.
Apoptotic markers showed significant dysregulation following thioacetamide treatment, with increased levels of both pro-apoptotic (Bax: 73% increase) and anti-apoptotic (Bcl-2: 220% increase) proteins, suggesting complex disruption of cell death pathways rather than simple activation of apoptosis. The elevation in Caspase-3 levels (268% increase) indicates significant activation of apoptotic execution pathways. Diosmin treatment normalized these parameters, bringing the Bax/Bcl-2 ratio closer to control values while reducing Caspase-3 levels by 59%. A similar dual upregulation of Bax and Bcl-2 in response to thioacetamide-induced liver injury was reported by
Abdel-Daim et al., (2020), suggesting that such dysregulation may reflect a compensatory cellular mechanism rather than a linear apoptotic response.
The histopathological findings provided crucial context for the biochemical changes observed. Thioacetamide induced severe architectural disruption, with formation of fibrous septa and regenerative nodules, characteristic of advanced liver fibrosis. Similar histopathological alterations were reported
Kundu et al., (2023), who observed dense fibrous septa, regenerative nodules and extensive collagen deposition following TAA administration in rats. Diosmin treatment significantly preserved hepatic architecture, with reduced fibrosis and inflammation, though some mild alterations persisted.
Together, these findings highlight diosmin’s multi-targeted protective effects against TAA-induced liver injury, involving antioxidant, anti-inflammatory and anti-apoptotic mechanisms.